LIQUIDIA CORPORATION Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
LIQUIDIA CORPORATION (LQDA) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $259.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2022-11-08
- 2022-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $259.00K.
- 2022-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $394.00K.
- 2022-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $524.00K.
- 2021-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $168.35K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2022-09-30 | $259.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $394.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $524.00K 10-Q · filed 2022-05-12 |
| 2021-09-30 | $168.35K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $246.17K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $323.52K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |